Ironwood Pharma (IRWD) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update
November 2, 2017 8:05 AM EDTIronwood revenue grew 31% to $87 million in 3Q 2017 over 3Q 2016
LINZESS® (linaclotide) U.S. net sales increased 16% to $191 million and net profit increased 36% to $111 million in 3Q 2017 over 3Q 2016
Launched DUZALLO® (lesinurad and allopurinol), a once-daily fixed-dose combination treatment for patients with uncontrolled gout
Advanced innovative development candidates with positive IW-3718 Phase IIb trial results and initiation of IW-1973 Phase II trials in diabetic nephropathy and HFpEF
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
